EXPRESSION--SYNTHETIC DNA SEQUENCES/HTLV-I ENV PROTEN

Information

  • Research Project
  • 3635137
  • ApplicationId
    3635137
  • Core Project Number
    N43CP095636
  • Full Project Number
    N43CP095636-000
  • Serial Number
    95636
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/16/1989 - 35 years ago
  • Project End Date
    -
  • Program Officer Name
  • Budget Start Date
    4/16/1989 - 35 years ago
  • Budget End Date
    10/15/1989 - 35 years ago
  • Fiscal Year
    1989
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

EXPRESSION--SYNTHETIC DNA SEQUENCES/HTLV-I ENV PROTEN

Human I-cell leukemia virus I (HTLV-I) is a transforming retrovirus etiologically associated with adult T-cell leukemia/lymphoma and troPical spastic ParaParesis. The number of HILV-I seropositive blood donors in the US is becoming alarmingly high raising concerns about contamination of transfusable blood products. Development of a highly-sensitive and highlyspecific blood-screening assay for HTLV-I antibodies in serum has been hindered by limiting quantities of certain viral proteins, including the most immunogenic protein, envelope. The proposed Phase I study outlines a strategy for expressing selected portions, as well as the entire envelope protein using synthetic DNA coding sequences. It is anticipated that this approach will allow these polypeptides to be expressed at high levels in E.coli. The expressed polypeptides will be analyzed biochemically and evaluated for their ability to detect antibodies to HTL7-I in human sera. In Phase II, promising candidate envelope polypeptides will be used to configure an enzyme-linked immunoassay (EIA) to detect antibodies to HTLV-I in human sera. The EIA will be evaluated for sensitivity and specificity using sera from a large number of normal and infected individuals. It is envisaged that a complementary set of recombinant-derived HTL7-I proteins will be configured into a high- quality blood-screening assay for exposure to this virus.

IC Name
DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
  • Activity
    N43
  • Administering IC
    CP
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    393
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
  • Study Section Name
  • Organization Name
    AMGEN, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    THOUSAND OAKS
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    91360
  • Organization District
    UNITED STATES